Asimadoline

Phase 3Small molecule

TTioga Pharmaceuticals

Asimadoline is one of 63 small molecule programs targeting Atopic Dermatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atopic DermatitisActive, not recruiting

Irritable Bowel SyndromeActive, not recruiting

Atopic DermatitisPhase 2

Active, not recruiting

Irritable Bowel SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

508 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

Skyrizi

AbbVie

Phase 3

2 2

Amlitelimab

Sanofi

Phase 3

6 3

Calcineurin Inhibitors

Sanofi

Phase 3

1 4

Elidel

Bayer

Phase 3

4 5

LNK01001

LLynk Pharmaceuticals Co., Ltd

Phase 3

2 6

Adquey

AAcrotech Biopharma Inc.

Phase 3

2 7

EBGLYSS

Eli Lilly

Preclinical

23 8

Cibinqo

Pfizer

Preclinical

11 9

Asimadoline

TTioga Pharmaceuticals

Phase 3

1 10

Ketotifen Fumarate

Tanabe Pharma Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Safety and Efficacy

NCT07042516

Clinical

Trials by Indication[1]

Irritable Bowel Syndrome3 trials

Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)

Completed·TTioga Pharmaceuticals·Phase 3·NCT01100684·611 enrolled

Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome

Completed·TTioga Pharmaceuticals·Phase 2·NCT00454688·596 enrolled

Effect of Asimadoline, a Member of a New Medication Class, on Acute Attacks of Pain in Irritable Bowel Syndrome

Completed·MMayo Clinic·Phase 2·NCT00955994·100 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).

Recruiting·TTioga Pharmaceuticals·Phase 2·NCT07042516·120 enrolled

Treatment1 trial

Asimadoline for the Treatment of Post-Operative Ileus

Terminated·TTioga Pharmaceuticals·Phase 2·NCT00443040·35 enrolled

Atopic Dermatitis1 trial

Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis

Completed·TTioga Pharmaceuticals·Phase 2·NCT02475447·249 enrolled

Adult1 trial

A Metabolite Identification, Mass Balance, and PK Study of [14C]-Asimadoline to Healthy Adult Male Volunteers

Completed·TTioga Pharmaceuticals·Phase 1·NCT01380561·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Asimadoline. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Asimadoline compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Asimadoline. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tioga Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTioga Pharmaceuticals

Asimadoline

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Irritable Bowel Syndrome3 trials

Safety and Efficacy1 trial

Treatment1 trial

Atopic Dermatitis1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News